Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 161-168

  Kay, Neil E ^a   Eckel Passow, Jeanette E ^a   Braggio, Esteban ^b   VanWier, Scott ^b   Shanafelt, Tait D ^a   Van Dyke, Daniel L ^a   Jelinek, Diane F ^a   Tschumper, Renee C ^a   Kipps, Thomas ^c   Byrd, John C ^d   Fonseca, Rafael ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PENTOSTATIN; PROTEIN P53; RITUXIMAB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CHEMOSENSITIVITY; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 3; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESPONSE; FEMALE; GENOMIC INSTABILITY; HUMAN; LEUKEMIC PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; GENE DELETION; GENES, P53; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 78650010643     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.09.003     Document Type: Article

References (21)

1. Shanafelt T.D., Geyer S.M., Kay N.E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103:1202-1210.
2. Wierda W.G., O'Brien S., Wang X., Faderl S., Ferrajoli A., Do K.A., et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007, 109:4679-4685.
3. Shanafelt T.D., Jenkins G., Call T.G., Zent C.S., Slager S., Bowen D.A., et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009, 115:363-372.
4. Byrd J.C., Gribben J.G., Peterson B.L., Grever M.R., Lozanski G., Lucas D.M., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24:437-443.
5. Kay N.E., Geyer S.M., Call T.G., Shanafelt T.D., Zent C.S., Jelinek D.F., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109:405-411.
6. Lin K.I., Tam C.S., Keating M.J., Wierda W.G., O'Brien S., Lerner S., et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009, 113:3168-3171.
7. Schlette E.J., Admirand J., Wierda W., Abruzzo L., Lin K.I., O'Brien S., et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 2009, 50:1597-1605.
8. Zenz T., Mertens D., Dohner H., Stilgenbauer S. Molecular diagnostics in chronic lymphocytic leukemia-pathogenetic and clinical implications. Leuk Lymphoma 2008, 49:864-873.
9. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
10. Dewald G.W., Brockman S.R., Paternoster S.F., Bone N.D., O'Fallon J.R., Allmer C., et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
11. Rassenti L.Z., Kipps T.J. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006, 70:209-213.
12. Jelinek D.F., Tschumper R.C., Geyer S.M., Bone N.D., Dewald G.W., Hanson C.A., et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001, 115:854-861.
13. Braggio E., Keats J.J., Leleu X., Van Wier S., Jimenez-Zepeda V.H., Valdez R., et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009, 69:3579-3588.
14. Lipson D., Aumann Y., Ben-Dor A., Linial N., Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol 2006, 13:215-228.
15. de Smith A.J., Tsalenko A., Sampas N., Scheffer A., Yamada N.A., Tsang P., et al. Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases. Hum Mol Genet 2007, 16:2783-2794.
16. Perry G.H., Ben-Dor A., Tsalenko A., Sampas N., Rodriguez-Revenga L., Tran C.W., et al. The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet 2008, 82:685-695.
17. McCarroll S.A., Kuruvilla F.G., Korn J.M., Cawley S., Nemesh J., Wysoker A., et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 2008, 40:1166-1174.
18. Gunnarsson R., Isaksson A., Mansouri M., Goransson H., Jansson M., Cahill N., et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010, 24:211-215.
19. Nelson B.P., Gupta R., Dewald G.W., Paternoster S.F., Rosen S.T., Peterson L.C. Chronic lymphocytic leukemia FISH panel: impact on diagnosis. Am J Clin Pathol 2007, 128:323-332.
20. Gunnarsson R., Staaf J., Jansson M., Ottesen A.M., Goransson H., Liljedahl U., et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemiaa comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008, 47:697-711.
21. Kujawski L., Ouillette P., Erba H., Saddler C., Jakubowiak A., Kaminski M., et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008, 112:1993-2003.